Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma. Update August 2021

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma. Update August 2021. Oncology Fact Sheet Nr. 50.

[thumbnail of Oncology Fact Sheet Nr.50_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
103kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WF Respiratory system
Language:	English
Series Name:	Oncology Fact Sheet Nr. 50
Deposited on:	17 May 2021 13:22
Last Modified:	31 Aug 2021 14:18

Repository Staff Only: item control page